AcuCort’s new, innovative drug enables fast uptake of the active ingredient dexamethasone. ISICORT® is not a tablet that must be swallowed nor does it require access to water since it is a fast-dissolving oral film to be put on the tongue. Important benefits in stressful situations such as acute and severe allergic reactions, not least for persons with swallowing difficulties.

What is AcuCort?

AcuCort develops and commercializes ISICORT® ‒ a new fast-dissolving oral film to be put on the tongue, based on a well-known version of cortisone – dexamethasone. ISICORT® is a smart product in a new, innovative and user-friendly administration form, primarily for the treatment of acute and severe allergic reactions, croup in children, chemotherapy-induced nausea and vomiting (CINV) as well as Covid-19 patients who need supplemental oxygen treatment.

The bioequivalence study that forms the basis of the application for marketing approval in Europe is carried out with positive results. On October 7, 2020, AcuCort received the market approval from the Swedish Medical Products Agency for the drug ISICORT®. This strengthens the company’s assessment that the time to commercialization may be relatively short. AcuCort AB’s share (ticker: ACUC) is listed on Spotlight Stock Market in Sweden.